Delving Into New Two-year Bimekizumab (Bimzelx, UCB) Data in Hidradenitis Suppurativa (HS) With Christopher Sayed, MD

March 10, 2025

New Two-year Data: Bimekizumab Provides Sustained Disease Control in HS

February 13, 2025

News You and Your Patients Can Use: New Dosing Option for UCB’s Bimekizumab Now Commercially Available for PsO, PsA, and HS

January 16, 2025

A Future Physician’s Journey With HS

December 2, 2024

Meeting Unmet Needs in HS With UCB’s Dr. Jeff Stark

November 25, 2024

What Does the Approval of Bimekizumab-bkzx (Bimzelx, UCB) Mean for the HS Community?

November 22, 2024

U.S. FDA Approves Bimekizumab-bkzx (Bimzelx, UCB) for HS

November 20, 2024

UNC Researchers Score Grant to Study Genetics of HS

October 11, 2024

HS Pipeline Watch: First Patient Dosed in Phase 2 Trial of AVTX-009; Topline Data Expected in 2026

October 8, 2024

EADV News: Bimekizumab Shows Long-term Efficacy and Safety in HS

September 27, 2024

Breaking News From EADV: Semaglutide Reduces Flares and Improves Quality of Life for Obese Patients With HS

September 24, 2024

The Patient’s Perspective: Diagnosing and Treating HS

August 29, 2024